Table 2.
Kaplan-Meier analysis of GRFS at 1 year and adjusted GRFS for the pediatric cohort (<21 years old)
| Frequency | Survival estimate | Log rank | ||||
|---|---|---|---|---|---|---|
| Factor | Strata | n | Events | Estimate | CI 95% | P value |
| Total conditioning* | 220 | 105 | 52% | 45-59 | ||
| MA | 209 | 95 | 55% | 49-61 | <.01 | |
| RIC | 11 | 10 | 14% | 1-33 | ||
| Stem cell source* | Marrow-matched sibling | 43 | 14 | 66% | 52-80 | .16 |
| PBSC-matched sibling | 9 | 3 | 68% | 38-98 | ||
| Marrow-/PBSC-matched URD | 13 | 8 | 50 | 25-75 | ||
| Single UCB | 95 | 45 | 53% | 43-63 | ||
| Double UCB | 60 | 35 | 43% | 31-55 | ||
| Gender | Male | 138 | 67 | 51% | 43-59 | .73 |
| Female | 82 | 38 | 54% | 42-64 | ||
| Diagnosis | ALL | 110 | 51 | 54% | 44-62 | .77 |
| AML | 72 | 33 | 54% | 42-65 | ||
| MDS/MPN/CML | 22 | 12 | 45% | 24-64 | ||
| NHL/Hodgkin/CLL | 16 | 9 | 44% | 20-66 | ||
| Disease risk* | Standard risk | 178 | 80 | 54% | 47-61 | .54 |
| High risk | 42 | 25 | 45% | 31-76 | ||
| CMV serostatus | Negative | 91 | 38 | 58% | 47-68 | .17 |
| Positive | 129 | 67 | 48% | 39-56 | ||
| GVHD prophylaxis | Csa or Tac with MTX | 94 | 41 | 56% | 46-66 | .49 |
| Csa or Tac with MMF | 124 | 63 | 49% | 40-58 | ||
| Other | 2 | 1 | 50% | 1-91 | ||
| Year of HCT* | 2000-2007 | 136 | 71 | 47% | 39-55 | .09 |
| 2008-2012 | 84 | 34 | 61% | 51-71 | ||
*
Denotes adjusted variable.